Recent studies have shown that classical EMT markers’ regulation (upregulation of N-cadherin and Vimentin and downregulation of E-cadherin) [47] can prompt GBM cells to assume the invasive mesenchymal subtype (MES) [4], contributing to both tumor progression and chemoresistance, as well as recurrence following treatment. Here, CDH2 is linked to glioblastoma.